Last Updated: May 10, 2026

Suppliers and packagers for generic pharmaceutical drug: griseofulvin, ultramicrosize


✉ Email this page to a colleague

« Back to Dashboard


griseofulvin, ultramicrosize

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Chartwell Rx FULVICIN P/G griseofulvin, ultramicrosize TABLET;ORAL 061996 ANDA Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc 23155-863-01 100 TABLET in 1 BOTTLE, PLASTIC (23155-863-01) 2023-06-30
Chartwell Rx FULVICIN P/G griseofulvin, ultramicrosize TABLET;ORAL 061996 ANDA Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc 23155-864-01 100 TABLET in 1 BOTTLE, PLASTIC (23155-864-01) 2023-06-30
Chartwell Rx FULVICIN P/G griseofulvin, ultramicrosize TABLET;ORAL 061996 ANDA Chartwell RX, LLC. 62135-494-01 100 TABLET in 1 BOTTLE, PLASTIC (62135-494-01) 1982-04-06
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Who Supplies Griseofulvin (Ultramicrosize) to the Market?

Last updated: April 23, 2026

Griseofulvin, ultramicrosize is an old, widely manufactured antifungal active ingredient. In practice, “supplier” visibility depends on whether you mean API producers (manufacturers of griseofulvin ultramicrosize as drug substance) or finished-dose manufacturers that sell ultramicrosize tablets/suspensions under brand or private-label. Without a specified geography, dosage form, and regulatory channel, supplier lists vary materially by jurisdiction.

What Categories of Suppliers Exist for Griseofulvin Ultramicrosize?

API suppliers

Companies that produce the drug substance (griseofulvin) in a particle-size specification described in “ultramicrosize” terms (typically tied to micronized/ultra-fine particle size used to improve dissolution).

Finished-dose (dosage form) manufacturers

Companies that commercialize ultramicrosize griseofulvin in tablets/suspensions for retail, hospital, and wholesale channels. These suppliers can be different from API suppliers because formulation and particle-size control can be handled upstream or through contract manufacturing.

Who Supplies Griseofulvin Ultramicrosize?

API (drug substance)

A complete, defensible list of API manufacturers for “ultramicrosize” requires verified sources tied to specific grades/particle-size specs and regulatory filings. The generic drug substance “griseofulvin” is widely available, but “ultramicrosize” is a specific performance/particle-size attribute, so supplier lists must be tied to that attribute.

Finished-dose suppliers

Finished-dose supply depends on the local market and is typically dominated by branded legacy products and multiple generic labels. “Ultramicrosize” labeling is common, but exact wording and strengths vary by country and regulatory dossier.

What Buyer-Visible Specs Define “Ultramicrosize”?

Particle-size specification

“Ultramicrosize” implies an engineered particle-size distribution intended to improve dissolution rate versus older larger-particle products. Buyers should require:

  • Documented particle-size distribution (laser diffraction or validated equivalent)
  • Batch-level confirmation of the ultramicrosize attribute tied to dissolution performance
  • COA that includes the relevant particle-size acceptance criteria for that product grade

Performance-linked testing

Finished-dose ultramicrosize products may require dissolution testing consistent with the approved spec for particle-size grade. Suppliers should provide:

  • COA with dissolution or a validated surrogate if specified
  • Stability protocols for the chosen formulation and particle-size grade

How to Build a Supplier Shortlist That Actually Matches “Ultramicrosize”

Contract and quality requirements

Procure only from suppliers that can provide:

  • Written confirmation that their griseofulvin is manufactured to an “ultramicrosize” particle-size grade (not only “micronized”)
  • Full documentation for particle-size distribution and acceptance criteria
  • Regulatory package linkage (for example: site master file or DMF/CEP references where applicable)

Qualification gates

  • Review facility GMP status and inspection history relevant to API/drug substance production
  • Perform incoming grade verification using the COA particle-size attributes and dissolution criteria (where relevant)
  • Require change control notifications for milling/jet-milling process changes that affect particle-size distribution

Key Takeaways

  • “Ultramicrosize” is a particle-size attribute tied to performance, so supplier qualification must be attribute-specific, not “griseofulvin generic” generic.
  • Supplier identification must distinguish API producers from finished-dose manufacturers, because the latter often controls formulation and particle-size attribute at the product level.
  • A defensible supplier shortlist requires particle-size distribution evidence, COAs tied to the ultramicrosize grade, and quality documentation that links to regulatory or performance specifications.
  • Without jurisdiction and dosage form constraints, a single definitive supplier list cannot be produced in a way that is accurate for “ultramicrosize” specifically.

FAQs

1) Is griseofulvin ultramicrosize the same as micronized griseofulvin?

No. “Ultramicrosize” is typically used for a finer, performance-linked particle-size grade with specific acceptance criteria and dissolution behavior.

2) Can any griseofulvin API supplier be used for ultramicrosize?

Not without verification. The supplier must document a particle-size grade that meets the ultramicrosize attribute used in the approved product specification.

3) Who is more important for ultramicrosize supply: API or finished-dose manufacturer?

Both matter, but for product performance and regulatory alignment, the finished-dose manufacturer’s particle-size control and dissolution spec alignment are usually decisive.

4) What documents should be required from a supplier for ultramicrosize?

At minimum: COA including particle-size distribution and its acceptance criteria; dissolution or performance-linked testing if specified; and documentation describing the ultramicrosize grade.

5) How do I avoid getting “generic griseofulvin” that fails ultramicrosize specs?

Use attribute-based procurement: require explicit ultramicrosize particle-size documentation and confirm it against incoming COA and (where relevant) dissolution or validated surrogates.

References

[1] European Pharmacopoeia. Griseofulvin monograph and related particulate/dissolution guidance (as applicable).
[2] U.S. Pharmacopeia (USP). Griseofulvin and relevant dissolution/particle-related provisions (as applicable).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing